Resumen de Blood-Based Screening for Colon Cancer: A Disruptive Innovation or Simply a Disruption?
This Viewpoint discusses the basis for the FDA’s 2016 approval of the blood-based septin 9 gene (SEPT9) assay as a screening test for colon cancer and concerns about its accuracy and use in clinical practice.
